• Cell and Gene Therapy Access Challenges

  • Dec 4 2024
  • Length: 53 mins
  • Podcast

Cell and Gene Therapy Access Challenges

Listen for free

View show details

  • Summary

  • In our second of three episodes in conjunction with members of ACCESS Forum, we engage with leading experts to uncover the multifaceted challenges of access and affordability in cell and gene therapies. Our conversation investigates how these treatments' innovative yet complex landscape leads to challenging regulatory pathways, pricing models, and reimbursement strategies.

    Alicia Silver, MPP, Head of Cell and Gene Therapy, ADVI Health
    Eric Faulkner, President, Passage Health Associates
    ADVI Health
    Alliance for Regenerative Medicine
    ARPA-H
    Bespoke Gene Therapy Consortium
    Blue Bird Bio
    Blue Cross Blue Shield
    Medicare DRG Rates
    NICE (National Institute for Health and Care Excellence)
    Novartis
    Passage Health Associates
    REMS Program
    Single Case Agreements
    Spark Therapeutics

    Medical terminology referenced in this episode:

    • Alzheimer's
    • Aspheresis
    • CAR T therapy
    • Hemophilia
    • Hepatitus C
    • Luxturna
    • Metachromatic leukodystrophy
    • Myeloablative Conditioning
    • Sickle Cell Disease
    • SMA treatment
    • Spinraza
    • Vaso Occlusive Crises
    • Zolgensma
    Show more Show less
Show more Show less
activate_Holiday_promo_in_buybox_DT_T2

What listeners say about Cell and Gene Therapy Access Challenges

Average Customer Ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.ca reviews

Amazon Reviews
No reviews are available